New frontiers for cardiac risk assessment: C-reactive protein.
Current theories of atherosclerotic plaque formation suggest that inflammation plays a key role in coronary heart disease. In an effort to augment current tools for cardiac risk assessment, researchers have found that levels of the inflammatory marker C-reactive protein (CRP) may play an important role in gauging an individual's risk for a cardiac event. While not currently recommended for mass population screening, measurement of CRP may play an increasing part in identifying at-risk patients and guiding pharmacologic intervention.
Caren McHenry
CM
Martin
Jina
J
Almond
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D050197:Atherosclerosis / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D006331:Heart Diseases / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000175:diagnosis; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D018570:Risk Assessment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D002097:C-Reactive Protein; D001241:Aspirin